一项随机对照试验:探讨正念认知疗法(MBCT)对改善心理治疗(IAPT)高强度治疗无应答抑郁症患者的临床有效性与成本效果的研究方案
本研究为两臂随机对照试验,纳入符合重性抑郁障碍诊断且对IAPT高强度治疗至少12次 sessions 应答不充分的患者,按1:1随机分配接受MBCT联合常规治疗或仅常规治疗。主要结局为随机化后34周采用PHQ-9评估的抑郁症状减轻程度,同时评估10周结局及成本效果。该试验旨在为IAPT路径中无应答者采用MBCT提供证据基础。
要点
- 研究对象为对IAPT高强度治疗至少12次 sessions 应答不充分的抑郁症患者。
- 主要结局为随机化后34周PHQ-9评估的抑郁症状减轻。
- 该试验为首次在心理治疗无应答后测试MBCT的试验。
核心结论
- 该试验将增加MBCT用于抑郁治疗无应答者的证据基础,并构成首个在心理治疗无应答后测试MBCT的试验,其结果可为IAPT路径内无应答者采用MBCT的决策提供重要依据。
研究设计与样本
- 两臂随机对照试验,患者按1:1比例随机分配接受MBCT联合常规治疗或仅继续常规治疗。
- 纳入当前符合重性抑郁障碍标准且对至少12次IAPT高强度治疗应答不充分的患者。
- 评估时间点为基线、随机化后10周和34周。
- 主要结局为随机化后34周采用PHQ-9评估的抑郁症状减轻。
- 次要结局包括随机化后10周抑郁症状及其他临床结局,以及二分类结局指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Major depression represents a pressing challenge for health care. In England, Increasing Access to Psychological Therapies (IAPT) services provide evidence-based psychological therapies in a stepped-care approach to patients with depression. While introduction of these services has successfully increased access to therapy, estimates suggest that about 50% of depressed patients who have come to the end of the IAPT pathway still show significant levels of symptoms. This study will investigate whether Mindfulness-Based Cognitive Therapy (MBCT), a group intervention combining training in mindfulness meditation and elements from cognitive therapy, can have beneficial effects in depressed patients who have not responded to high-intensity therapy in IAPT. It will seek to establish the effectiveness and cost-effectiveness of MBCT as compared to the treatment these patients would usually receive. METHODS: In a 2-arm randomised controlled trial, patients who currently meet the criteria for major depressive disorder and who have not sufficiently responded to at least 12 sessions of IAPT high-intensity therapy will be allocated, at a ratio of 1:1, to receive either MBCT (in addition to treatment as usual [TAU]) or continue with TAU only. Assessments will take place at baseline, 10 weeks and 34 weeks post-randomisation. The primary outcome will be reduction in depression symptomatology 34 weeks post-randomisation as assessed using the Public Health Questionnaire-9 (PHQ-9). Secondary outcomes will include depressive symptomatology at 10 weeks post-randomisation and other clinical outcomes measured at 10-week and 34-week follow-up, along with a series of binarised outcomes to indicate clinically significant and reliable change. Evaluations of cost-effectiveness will be based on assessments of service use costs collected using the Adult Service Use Schedule and health utilities derived from the EQ-5D. DISCUSSION: This trial will add to the evidence base for the use of MBCT in depressed treatment non-responders. It will constitute the first trial to test MBCT following non-response to psychological therapy, with results providing a direct estimate of efficacy within the IAPT pathway. As such, its results will offer an important basis for decisions regarding the adoption of MBCT for non-responders within IAPT. TRIAL REGISTRATION: ClinicalTrials.gov NCT05236959. Registered on 11 February 2022. ISRCTN 17755571. Registered on 2 February 2021.
引用
- Barnhofer T, Dunn BD, Strauss C, et al. A randomised controlled trial to investigate the clinical effectiveness and cost effectiveness of Mindfulness-Based Cognitive Therapy (MBCT) for depressed non-responders to Increasing Access to Psychological Therapies (IAPT) high-intensity therapies: study protocol. Trials. 2023. PMID: 36658663. doi:10.1186/s13063-022-06882-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。